Regulatory
Published · Updated · 2 min read
DEC: reproductive risks of sodium valproate in the Vinitel risk management plan
What it means for practice
Valproate treatment for epilepsy requires specialist oversight, particularly in high-risk groups. Consider reproductive contraindications and pregnancy prevention measures; their exact conditions must be checked against the original document.
Summary
The website of the State Expert Centre of the Ministry of Health of Ukraine hosts a document concerning the risk management plan for Vinitel syrup, which contains sodium valproate. According to the description attached to the link, the main focus is teratogenicity and neurodevelopmental problems in children exposed to the medicine in utero.
Risk minimization measures
The plan describes routine and additional risk minimization measures. These include contraindications concerning pregnant women and women of childbearing potential, as well as effective contraception. The attached description does not specify the conditions of these contraindications and should therefore not be used as complete prescribing guidance for these groups.
Monitoring and practical implications
The document provides for ongoing pharmacovigilance activities to collect and analyze adverse reaction data. It emphasizes specialist oversight during valproate treatment for epilepsy, particularly in high-risk groups.
The available description provides neither quantitative risk estimates nor information about a new change in regulatory requirements. Specific conditions of use and risk minimization measures need to be checked in the original document.
Source
-
Вінітел, сироп, ТОВ “КУСУМ”, Україна.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
